The gene therapy industry has continued to rapidly expand over the last year as exciting new platforms are emerging onto the space, while existing players look to advance to the next generation. Leaps and bounds have been made towards better and safer vectors in response to safety and toxicity concerns.

During this IP explosion, the 3^rd Next Generation Gene Therapy Vectors Summit brought together key leaders in a highly technical setting to decide the future of the industry. Shifting focus from last year, we featured a deeper dive into AAV vector design and the next generation vector systems competing with it.

Attendees heard from experts across 3 days of technical panel discussions, platform showcases, case studies and seminars. This allowed them to the next generation with the only summit aimed at improving the safety, toxicity, specificity, and scalability of the current generation of gene therapy vectors.